SCHEMBL347406

SCHEMBL347406

Cc1noc([C@@H](C)NC(=O)c2ccc3c(-c4ccc(F)cc4F)n(CCO)nc3c2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 2/20 0.42
ROCK2 O75116 8/20 0.41
GABRA5 P31644 1/20 0.38
RIPK1 Q13546 1/20 0.38
KCNT1 Q5JUK3 3/20 0.36
DPP4 P27487 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
RPS6KA5 O75582 1/20 0.35
MAP4K4 O95819 1/20 0.35
PRKCG P05129 1/20 0.35
CDK1 P06493 1/20 0.35
PRKACA P17612 1/20 0.35
RPS6KB1 P23443 1/20 0.35
CDK2 P24941 1/20 0.35
MAPK1 P28482 1/20 0.35
AKT1 P31749 1/20 0.35
AKT2 P31751 1/20 0.35
FLT4 P35916 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347398 0.77 ALDH1A1 (0.41) DGAT2GABRA5RIPK1KCNT1
SCHEMBL13104922 0.71 GABRA5 (0.39) DGAT2ROCK2GABRA5RIPK1DPP4
SCHEMBL13092739 0.70 KCNT1 (0.41) DGAT2GABRA5RIPK1KCNT1DPP4
SCHEMBL3058052 0.69 NR1I2 (0.49) DGAT2GABRA5RIPK1KCNT1DPP4
SCHEMBL13095475 0.69 GABRA5 (0.40) DGAT2GABRA5RIPK1KCNT1DPP4
SCHEMBL21048472 0.69 WDR5 (0.38) DGAT2ROCK2GABRA5RIPK1KCNT1
SCHEMBL3070727 0.69 WDR5 (0.38) DGAT2ROCK2GABRA5RIPK1KCNT1
SCHEMBL366472 0.67 DGAT2 (0.42) DGAT2GABRA5RIPK1KCNT1DPP4
SCHEMBL348103 0.67 DGAT2 (0.42) DGAT2GABRA5RIPK1KCNT1DPP4
SCHEMBL452218 0.66 RAB9A (0.39) DGAT2ROCK2RIPK1KCNT1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411001-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2018-01-17 EP disclosed
US-8569512-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2013-10-29 US disclosed
US-20120015052-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME LLC 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015052-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 DGAT2 3948/4885ROCK2 4372/4885GABRA5 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.